<DOC>
	<DOCNO>NCT00355615</DOCNO>
	<brief_summary>The primary objective study determine efficacy once-daily rosuvastatin reduce LDL-C child adolescent age 10-17 year HeFH baseline ( Day 0 ) end 12-week double-blind treatment period .</brief_summary>
	<brief_title>PLUTO : Pediatric Lipid-redUction Trial rOsuvastatin</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Male female ( least 1 year postmenarche ) child adolescent ( age 10 17 year ) heterozygous familial hypercholesterolemia ( HeFH ) Certain medical condition lab test result History reaction rosuvastatin statin drug Use specify disallowed medication</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Heterozygous Familial Hypercholesterolemia</keyword>
</DOC>